Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PYGL | P06737 | 10/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7985019 | 0.85 | SMN1; SMN2 (0.54) | HPGDRAB9AGAA | |
| Methylamine SCHEMBL7258774 | 0.82 | SMN1; SMN2 (0.51) | HPGDPYGLGAA | |
| SCHEMBL3147754 | 0.81 | KDM4E (0.68) | HPGDNPC1RAB9APYGLFLT1 | |
| SCHEMBL4154496 | 0.81 | KDM4E (0.67) | HPGDNPC1RAB9APYGLFLT1 | |
| SCHEMBL29833777 | 0.81 | KDM4E (0.67) | HPGDNPC1RAB9APYGLFLT1 | |
| SCHEMBL909599 | 0.81 | CES2 (0.61) | NPC1RAB9AGAA | |
| SCHEMBL6417292 | 0.81 | POLB (0.66) | HPGDNPC1RAB9APYGLFLT1 | |
| SCHEMBL883797 | 0.81 | NPC1 (0.59) | HPGDNPC1RAB9APYGLCTSL | |
| SCHEMBL883600 | 0.81 | HPGD (0.56) | HPGDNPC1RAB9APYGLGAA | |
| SCHEMBL17143174 | 0.80 | PYGL (0.54) | HPGDRAB9APYGLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3383853-B1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR (LXR) BETA AGONISTS FOR TREATING E.G. ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3383853-B1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR (LXR) BETA AGONISTS FOR TREATING E.G. ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| EP-2298747-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
| EP-1171419-B1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| CN-1152006-C | Biphenyl derivatives | - | 2004-06-02 | — | — | CN | disclosed |
| US-6552088-B2 | 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor | HOFFMANN-LA ROCHE INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020040060-A1 | Biphenyl derivatives | BOS MICHAEL (CA) | 2002-04-04 | — | — | US | disclosed |
| CN-1343197-A | Biphenyl derivatives as neurokinin-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2002-04-03 | — | — | CN | disclosed |
| EP-1171419-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| US-6291465-B1 | Biphenyl derivatives | HOFFMANN-LA ROCHE INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000053572-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | NR1H2, NR1H3, NR1H4 | HPGD 1249/4885NPC1 134/4885RAB9A 1109/4885 |
| US-20020040060-A1 | Biphenyl derivatives | NR1H4, NR1H2, NR1H3 | HPGD 2019/4885NPC1 181/4885RAB9A 2043/4885 |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | HPGD 951/4885NPC1 97/4885RAB9A 1973/4885 |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | HPGD 951/4885NPC1 97/4885RAB9A 1973/4885 |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | HPGD 951/4885NPC1 97/4885RAB9A 1973/4885 |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | HPGD 951/4885NPC1 97/4885RAB9A 1973/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | HPGD 1749/4885NPC1 17/4885RAB9A 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.